UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/891,256	06/27/2001	Ake R. Lindahl	28069-531001US	1609
	7590 09/17/200 I COHN FERRIS GLO	EXAMINER		
ONE FINANCIAL CENTER			PAK, JOHN D	
BOSTON, MA 02111			ART UNIT	PAPER NUMBER
			1616	
			MAIL DATE	DELIVERY MODE
			09/17/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
09/891,256	LINDAHL, AKE R.	
Examiner	Art Unit	
John Pak	1616	

	John Pak	1616	
The MAILING DATE of this communication appe	ars on the cover sheet with th	e correspondence add	ress
THE REPLY FILED 08 September 2009 FAILS TO PLACE THI		=	
The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Apperior Continued Examination (RCE) in compliance with 37 C periods:	the same day as filing a Notice replies: (1) an amendment, affideal (with appeal fee) in compliance	of Appeal. To avoid abar avit, or other evidence, v be with 37 CFR 41.31; o	which places the r (3) a Request
a) The period for reply expires 6 months from the mailing date b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire la	dvisory Action, or (2) the date set for ater than SIX MONTHS from the ma	ling date of the final rejection	on.
Examiner Note: If box 1 is checked, check either box (a) or (MONTHS OF THE FINAL REJECTION. See MPEP 706.07(1) Extensions of time may be obtained under 37 CFR 1.136(a). The date). on which the petition under 37 CFR	1.136(a) and the appropriat	te extension fee
have been filed is the date for purposes of determining the period of ext under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the s set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	hortened statutory period for reply o than three months after the mailing	riginally set in the final Offic	ce action; or (2) as
 The Notice of Appeal was filed on <u>08 September 2009</u>. A the date of filing the Notice of Appeal (37 CFR 41.37(a)), a appeal. Since a Notice of Appeal has been filed, any reply AMENDMENTS 	or any extension thereof (37 CFI	R 41.37(e)), to avoid disr	missal of the
3. ☑ The proposed amendment(s) filed after a final rejection, b (a)☑ They raise new issues that would require further cor	out prior to the date of filing a bri nsideration and/or search (see N	ef, will <u>not</u> be entered be OTE below);	cause
(b) ☐ They raise the issue of new matter (see NOTE belo (c) ☐ They are not deemed to place the application in bet	• •	reducing or simplifying t	he issues for
appeal; and/or (d) ☑ They present additional claims without canceling a c NOTE: <u>See Continuation Sheet</u> . (See 37 CFR 1.1		ejected claims.	
4. The amendments are not in compliance with 37 CFR 1.12	* **	Compliant Amendment (PTOL-324)
5. Applicant's reply has overcome the following rejection(s):			1 1 OL-324).
 Newly proposed or amended claim(s) would be all non-allowable claim(s). 		e, timely filed amendme	nt canceling the
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is prove The status of the claim(s) is (or will be) as follows:		will be entered and an e	xplanation of
Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: <u>1-49</u> .			
Claim(s) withdrawn from consideration: AFFIDAVIT OR OTHER EVIDENCE			
 The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 	I sufficient reasons why the affid	avit or other evidence is	necessary and
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary 	vercome <u>all</u> rejections under app	eal and/or appellant fail	s to provide a
10.		•	
11. The request for reconsideration has been considered but See Continuation Sheet.	,		ce because:
12.	PTO/SB/08) Paper No(s)	-	
	/John Pak/ Primary Examiner, Ar	Unit 1616	

Continuation of 3, NOTE: Compositions 6, 7 and 11 as set forth in specification Table 3 were indicated as being allowable in the Office action of 3/5/09, wherein it was further noted that there was at that time no single claim that was directed to such subect matter. In response, applicant proposes to cancel claims 1-49 and add claims 50-104. First, applicant has added more claims than those that have been canceled. Second, the claim changes are quite extensive and they require further consideration. Third, potential new matter issue is raised because applicant is attempting to take the compositions 6, 7 and 11 of Table 3 and expanding its scope by, inter alia, reciting amounts in terms of "about." The compositions of Table 3 were not originally disclosed to cover amounts in terms of "about." With such specific ingredients and specific amounts as in compositions 6, 7 and 11, wherein acceptable initial pH and storage pH are obtained, it would not have been reasonably conveyed that variations in amounts was disclosed for compositions 6, 7 and 11. One of ordinary skill in the art would not be able to ascertain the metes and bounds of "about" under the present fact situation because (a) no disclosure of "about" (what does it cover and not cover?) was disclosed in the context of a composition as specific as compositions 6, 7 and 11, and (b) it would not be predictable whether the data obtained with the specific combination and proportions of ingredients in Table 3 could be repeated with different combinations and proportions. Fourth, in claim 50 for example, 1-35 wt% of at least one monoglyceride is recited, but at least one monoglyceride is about 21 wt% 1-glycerolmonomyristate. This is confusing language since the 21 wt% monoglyceride would seem to preclude the lower ranges of 1-35 wt%. Fifth, in claim 50 for example, the monoglyceride component (ii) is not commensurate in scope with compositions 6, 7 and 11 because those compositions specifically contain 7 wt% 1-glyceryl monolaurate and 21 wt% 1-glyceryl monomyristate, both of which are in crystalline form. In other independent claims, applicant attempts to vary some weight percentages or not specifying weight percentages of some of the components of compositions 6, 7 and 11. Again, such amendments would raise and require further consideration as to new matter and whether the data for compositions 6, 7 and 11 could support nonobviousness of expanded scope, as proposed herein. At this after-final stage of prosecution, such extensive amendments and further consideration of new issues raised are deeemed untimely.

Continuation of 11. does NOT place the application in condition for allowance because: the claims have not been amended to be limited strictly to compositions 6, 7 and 11 of specification Table 3, as fully discussed in the Note to item 3 of this Advisory Action, which resulted in the non-entry of the proposed after-final amendments. For the reasons of record, claims 1-49 remain rejected.